Key result
Centrally acting ACE inhibitors were associated with a 25% reduction in the 12-month rate of functional decline in patients with Alzheimer's disease compared to no CACE-I use (p=0.024).
Why the study?
Do centrally acting angiotensin converting enzyme inhibitors reduce functional decline in patients with mild to moderate Alzheimer's disease?
Population
365 patients with mild to moderate Alzheimer's disease from the Doxycycline and Rifampicin for Alzheimer's…
Comparison
Centrally acting angiotensin converting enzyme… vs No current treatment with CACE-Is (NoCACE-I)
Design
Cohort
Follow-up
12 months
Authors
Loading...
Hypothesis-generating for centrally acting ACE inhibitors slowing decline in Alzheimer's; prospective randomized trials needed before clinical adoption.
Observational (n=406)
Do centrally acting angiotensin converting enzyme inhibitors reduce functional decline in patients with mild to moderate Alzheimer's disease?
Effect estimate: 25% difference
p-value: p=0.024
Centrally acting ACE inhibitors, particularly perindopril, may slow functional decline in patients with mild to moderate Alzheimer's disease.
Ó’Caoimh et al. (2014) conducted an observational in Mild to moderate Alzheimer's disease (n=406). Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) vs. NoCACE-I (not currently treated with CACE-Is) was evaluated on 12-month rate of decline in ADL scores (25% difference, p=0.024). Centrally acting ACE inhibitors were associated with a 25% reduction in the 12-month rate of functional decline in patients with Alzheimer's disease compared to no CACE-I use (p=0.024).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: